WL Gore & Associates has reported that the first patient case involving the Gore DrySeal Sheath. The sheath aids in minimally invasive treatment for patients with abdominal aortic aneurysms (AAA) with the Gore Excluder AAA Endoprosthesis and thoracic aortic aneurysms (TAA) with the Gore TAG Thoracic Endoprosthesis.
Gore has received FDA clearance in April 2010 to market DrySeal Sheath, which is comprised of the hemostatic Gore DrySeal Valve attached to the introducer sheath. The Gore DrySeal Valve is pressurised to create a seal, thereby minimising blood loss and accommodating multiple wires and catheters simultaneously.
The valve consists of a silicone outer tube and an inner film tube that create an effective hemostatic seal that easily adapts to the profiles of the inserted devices. The device is available in profiles from 12 to 26 Fr, in 2 Fr increments, and has a working length of 28 cm.
Lumsden, chairman of the department of cardiovascular surgery at The Methodist Hospital (TMH) in Houston, said: “The ability of the Gore DrySeal Valve to accommodate multiple devices during difficult procedures with minimal blood loss keeps the operating field free from excess blood, while helping to prevent unnecessary blood loss to the patient.
“The Gore DrySeal Sheath requires no intra-procedural manipulation of the valve, delivering consistent performance throughout the procedure and allowing the physician to maintain focus on the endovascular procedure without being concerned about blood loss at the patient access site.”
David Abeyta, aortic business leader at Gore said: “This latest addition to Gore’s portfolio of world-class endovascular devices and accessory products minimizes patient blood loss during procedures with endovascular devices, such as the Gore Excluder AAA Endoprosthesis.”